NCT03519230 2026-03-16
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
BeOne Medicines
Phase 3 Active not recruiting
BeOne Medicines
University of California, San Francisco
M.D. Anderson Cancer Center
St. Joseph's Hospital and Medical Center, Phoenix
Anhui Provincial Cancer Hospital